Smoking Cessation - Data, Analysis & Forecasts to 2023

Product code:CB1

Availability: In stock

€2,499.00

Qty: Buy Now - OR -

'Smoking Cessation - Data, Analysis & Forecasts till 2023' 

Pharmaceutical, Commercial & Strategic Developments in the Global Smoking Cessation Market 2013-2023

  

In April 2013 the US Food & Drug Agency (FDA) announced its plan to relax rules regarding the use and labelling of over-the-counter nicotine replacement therapies.

 

On April 1st 2013, FDA Commissioner Margaret A. Hamburg M.D. stated, “The agency heard from several public health groups that the labelling for OTC NRT products may stop consumers who are trying to quit smoking from using them. The FDA hopes the recommended changes will allow more people to use these products effectively for smoking cessation and that tobacco dependence will decline in this country.” Will new changes increase take-up of smoking cessation products? This report tells you.

 

The global smoking cessation market is forecast to reach $4.4bn in 2023, but what will it be this year? Next year? and in 5 years time?

 

GMR Data’s new smoking cessation report outlines the key factors affecting the market across the forecast period 2013-2023. The report outlines essential drivers and restraints in all key global geographies.

 

Nicoderm and Habitrol are the primary NRT products on the market, accounting for over 80% of the global NRT market revenue in 2013. Bupropion and Varenicline are the major products in the prescription drug segment of the smoking cessation market. But what are the 5 key drivers of the global smoking cessation market?

 

1) Increased health care / health education in many geographies

2) Adoption of smoking cessation products onto health insurance policies

3) Increasing number of smoking cessation products emerging onto the market

4) Emergence of e-cigarettes onto the global market

5) Over 1bn smokers worldwide

 

This report analysis your market, in key geographic segments; explains in which direction each key market will grow across the next 10 years, and why. Can you afford to ignore this report?

 

Key challenges for you & your competition

 

The key challenges that must be faced in the smoking cessation market include; a weak R&D pipeline, off putting side effects affecting key smoking cessation drugs and the challenge of multiple e-cigarette brands encroaching the traditional NRT marketplace.

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.

 

This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.

  

Discover exactly what the industry leaders are doing TODAY -  

 

Within GMR Data’s ‘Smoking Cessation - Data, Analysis & Forecasts to 2023’ we analyse the key cessation products and drugs in the market currently and how they will perform across the next decade.

Our study focuses on the individual revenues of the top Smoking Cessation products. With variable patents and the threat of generics, how will these key products fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU

We also include analysis of key NRT (Nicotine Replacement Therapies such as NicoDerm CQ; Nicotrol; Habitrol (Nicotinell) and Nicorette. Also analysed are the prescription drugs for smoking cessation, such as:  Chantix (by Pfizer): Varenicline and Zyban / Wellbutrin (by GSK): bupropion.

With assessment of the leading players in smoking cessation including: Pfizer; GlaxoSmithKline (GSK); Novartis; Johnson & Johnson (J&J); Perrigo; Sophomore and Extab plus 22nd Century Group, Inc.

 

PLUS – In-depth country analysis – Discover which countries and regions will drive the smoking cessation drugs market to 2023?

Prescription drugs in the smoking cessation have proved popular and, to some extent, effective. However, side effects and increasingly severe FDA warnings have put some potential customers off. What this means is that there is still space in the market for new pipeline drugs, with fewer side effects and greater efficacy.

But how will these prescription markets develop? This report will tell you - TODAY

 

Industry information sourced exclusively for this report. This information is not available anywhere else

 

Utilising primary and secondary research sources, GMR Data have interviewed leading smoking cessation specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Smoking Cessation products. This report will arm you with all you and your company require to develop, price, launch and market a smoking cessation product.

With over 100+ pages, and over 85+ pages of charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

 

To order this report please contact Alice Morgan on TEL: +353 86 075 2687 or by emailing Alice.Morgan@GMRData.com

Smoking Cessation –Data, Analysis & Forecast to 2023

 

Pharmaceutical, Commercial, & Strategic Developments in the Global Smoking Cessation Market

 

1 Executive Summary

 

1.1. Smoking Cessation Market Review

1.2. Chapter Breakdown

1.3. Research and Analysis Methods

 

 2  Introduction to Smoking Cessation

 

2.1. Smoking Cessation Treatment Overview

2.1.1. Nicotine Replacement Therapy (NRT)

2.1.2. Non-NRT Therapy

2.2. Global Tobacco Consumption Prevalence, Trends & Impact

2.2.1. Prevalence of Death Caused due to Tobacco

2.2.2. Second-Hand Smoking

2.2.3. Increased Awareness of Health Implications in Relation to Smoking

2.2.4. Enforcement of Bans on Tobacco Product Advertising & Promotions

2.2.5. Increased Taxation

 

3 Smoking Cessation Market Forecasts

 

3.1. Global Smoking Cessation Market

3.1.1. Global Smoking Cessation Market

3.1.2. Global Prescription Drugs Smoking Cessation Market

 

4 Key Global Smoking Cessation Markets 2013-2023

 

4.1. The US Smoking Cessation Market - Set to Occupy 45-50% of the Global Market Across 2013- 2023

4.2. The UK Smoking Cessation Market - How Will This Mature Market Grow Through 2013-2023?

4.3. The France Smoking Cessation Market - How Much of the Global Smoking Cessation Market Will France Occupy to 2023?

4.4. The German Smoking Cessation Market - Will Reduced German Tobacco Consumption Drive The Smoking Cessation Market?

4.5. The Spanish Smoking Cessation Market - The Strictest Anti-Smoking Laws in the EU, How Will This Affect The Spanish Smoking Cessation Market?

4.6. The Italian Smoking Cessation Market - How Will Strong E-cigarette Sales Affect Other NRT Products in the Italian Smoking Cessation Market?

4.7. The Japanese Smoking Cessation Market - Why Does GMR Data Forecast a Low Growth Rate in the Japanese Smoking Cessation Market?

4.8. The Rest of World Smoking Cessation Market - How Will Emerging Markets, Such as India & China, Affect theGlobal Smoking Cessation Market Across 2013-2023?

 

5 Nicotine Replacement Therapies (NRT) Market

 

5.1. NicoDerm CQ

5.2. Nicotrol

5.3.Habitrol (Nicotinell)

5.4.Nicorette 

 

6 Prescription Drugs Smoking Cessation Market

 

6.1.Chantix (by Pfizer): Varenicline

6.2.Zyban / Wellbutrin (by GSK): bupropion

 

7 Leading Companies in the Global Smoking Cessation Market

 

7.1. Pfizer

7.2. GlaxoSmithKline (GSK)

7.3. Novartis

7.4. Johnson & Johnson (J&J)

7.5. Perrigo

7.6. Sophomore and Extab

7.7. 22nd Century Group, Inc.

 

8 SWOT Analysis of the Smoking Cessation Market

 

8.1. Strengths

8.1.1. FDA Relaxation in the NRT Market

8.1.2. Increased Insurance Cover for Smoking Cessation Products

8.1.3. Strong Mature Markets

 

8.2. Weaknesses

8.2.1. Weak R&D pipeline for the smoking cessation market

8.2.2. Side Effects to Current Drugs/Therapies on the Market

 

8.3. Opportunities

8.3.1. E-cigarettes

8.3.1.1. E-cigarettes Legal Status

8.3.1.2. E-cigarettes Background

8.3.1.3. Geographic Breakdown & Market Share for E-cigarettes

8.3.1.4. Market Forecast

8.3.1.5. E-cigarette Industry Regulation

8.3.2. Future Research on Drugs/Therapies Currently on the Market

8.3.3. Strong Emerging Markets

 

8.4. Threats

8.4.1. Pool of Smokers Greatly Reduced in Some Key Markets

8.4.2. New Drug / Product threat

 

9 Expert Interviews

 

9.1. Pfizer

9.2. Elder Pharmaceuticals

9.3. GlaxoSmithKline

 

List of Tables

 

Table 2.2.1 Prevalence of tobacco use among adults in selected countries—males and females, 2010

Table 2.2.2: Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010

Table 2.2.3: BRIC Population, GDP per Capita 2000 & 2010 ($/per annum)

Table 2.2.3.1: Smokers Reporting Six Months Continued Cessation with Different Interventions

Table 2.2.3.2: Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country

Table 3.1 Global Smoking Cessation Market Forecast 2013-2023 ($m)

Table 3.1.a: Key NRT Products Revenue Forecast 2013, 2018 & 2023 ($/m)

Table 3.1.b Global Smoking Cessation Market - Breakdown ($m)

Table 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023 ($/m)

Table 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023 ($/m)

Table 4.a The Global Smoking Cessation Market Forecast 2012 -2023, by Country ($/m per annum)

Table 4.b Key Countries CAGR 2013-2023 (%)

Table 4.c Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)

Table 4.1 the US Smoking Cessation Market Forecast 2011-2023 ($/m)

Table 4.2 the UK Smoking Cessation Market Forecast 2012-2023 ($/m)

Table 4.2.1 EU5 Total Population & Population of Smokers 2012

Table 4.3 the France Smoking Cessation Market Forecast 2011-2023 ($ Million)

Table 4.4 the German Smoking Cessation Market Forecast 2011-2023 ($/m)

Table 4.4.1 Amount of Tobacco Sold in Germany 1995-2010 (Tonnes)

Table 4.5 the Spanish Smoking Cessation Market Forecast 2011-2023 ($ Million)

Table 4.5.1 The number of smokers in Spain (Million)

Table 4.6 The Italian Smoking Cessation Market Forecast 2011-2023 ($/m)

Table 4.7 the Japanese Smoking Cessation Market Forecast 2011-2023 ($/m)

Table 4.8 The Rest of the World Smoking Cessation Market Forecast 2011-2023 ($ Million)

Table 4.8.1 Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)

Table 4.8.2 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($/per annum)

Table 5.1 Market Forecast for Nicoderm CQ 2013-2023

Table 5.2 Global Nicotrol Market 2010-2012 ($m)

Table 5.2.1 Global Nicotrol Market Forecast 2013-2023 ($/m)

Table 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023

Table 5.4 Market Forecast for Nicorette 2013-2023

Table 6 Tobacco Cessation Medications and Associated Side Effects

Table 6.1 Global Chantix/ Champix Market 2008 – 2012

Table 6.1.a Market Forecast for Chantix / Champix 2013-2023

Table 6.2 Market Forecast for Zyban 2013-2023

Table 7.1 Pfizer Smoking Cessation Pipeline

Table 7.2 Global Chantix / Champix Market 2008-2012

Table 7.3 Market Forecast for Chantix / Champix 2013-2023

Table 7.4 Market Forecast for Zyban 2013-2023

Table 8 SWOT Analysis

Table 8.1.3 US, UK, France & Japanese Smoking Cessation Markets 2012-2016 ($/ per annum)

Table 8.2.1 NRT Products Pipeline

Table 8.2.1.a Smoking Cessation Drugs /Products Pipeline

Table 8.2.2 Side Effects of major smoking cessation products

Table 8.3.1.2 Major E-cigarette Brands

Table 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023

Table 8.3.1.4.a Costs per pack of cigarettes in Key countries

Table 8.3.3ROW Smoking Cessation Market Share 2013

Table 8.3.3.a Chinese & Indian Populations, Number of Smokers, GDP in 2000 & 2010 ($)

 

 

List of Figures

 

 

 

Figure 2.2.1: Prevalence of tobacco use among adults in selected countries—males and females, 2010

Figure 2.2.4.1 Global Market Size as per Skin Cancer Type – Incidences

Figure 2.2.2 Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010

Figure 2.2.3 Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country

Chart 2.2.5: Average Retail Price and Taxation (Excise and Total) of Most Sold Brands of Cigarettes, 2010

Figure 3.1 Global Smoking Cessation Market Forecasts 2013 to 2023

Figure 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023

Figure 3.1.1.a Global NRT Smoking Cessation Market Share by Product Type

Figure 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023

GMR Data 2013

Figure 4.a Global Market Share for Selected Countries 2013

Figure 4.b Global Market Share for Selected Countries 2018

Figure 4.c Global Market Share for Selected Countries 2023

Figure4.1. The US Smoking Cessation Market Forecast 2012-2023 ($/m)

Figure 4.2 Retail Sales of NRT Products in the UK 2012

Figure 4.2.a. The UK Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 4.3. The France Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 4.4 The German Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 4.5. The Spanish Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 4.6 The Italian Smoking Cessation Market Forecast 2012-2023 ($/m)

Figure 4.7 The Japanese Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 4.8 The ROW Smoking Cessation Market Forecast 2012-2023 ($ Million)

Figure 5.1 Market Forecast for Nicoderm CQ 2013-2023

Figure 5.1.a Geographic Breakdown for Nicoderm CQ 2012 & 2023

Figure 5.2 Global Revenue for Nicotrol 2010-2012

Figure 5.2.1 Global Market Forecast for Nicotrol 2013-2023

Figure 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023

Figure 5.4 Market Forecast for Nicorette 2013-2023

Figure 6.1 Global Chantix/ Champix Market 2008 – 2012

Figure 6.1.a Global Chantix/ Champix Market 2013 – 2023

Figure 6.1.b Geographic Breakdown for Chantix / Champix 2012 & 2023

Figure 6.2 Global Zyban Market 2013 – 2023

Figure 8.3.1.3 Geographic Breakdown

Figure 8.3.1.3.1 Market Share of e-cigarette Sales in the US Convenience Stores by Brand

Figure 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023

 

22nd Century Group, Inc

Acrux

Alcon Inc

Altria Group Inc

Alza Corporation

American Lung Association and Cancer Advocacy Coalition of Canada

Aradigm Corporation

Biota Holdings Ltd

Biota Pharmaceuticals, Inc.

Birlaveda

British American Tobacco

Celtic Pharmaceuticals

Cipla

CN Creative

Cytos Biotechnology

Elder Pharmaceuticals limited

EverSmoke Electronic Cigarettes

Evotec AG

Extab Corporation

Frii Inc

GlaxoSmithKline

Green Smoke Inc

Imperial Tobacco

Independent Pharmaceutica AB

Institute of Human Behaviour & Allied Sciences

Invion Limited

Johnson & Johnson

KLOX Technologies

Lorillard Inc

McNeil

Nabi Biopharmaceuticals

NAL Pharmaceuticals

National Institute on Drug Abuse

Nicobrand

Niconovum AB

NJOY

Novartis

Nu Mark LLC

Perrigo

Pfizer Inc

Pure Cigs, LLC

Reynolds American Inc

RML Hospital and Chronic Care Foundation

Sandoz Pharmaceuticals

Selecta Biosciences, Inc

Shanghai Johnson & Johnson Pharmaceutical Ltd

Sopharma

South Beach Smoke

Sun Pharma

Taranabant, Merck & Co

Teva Pharmaceuticals

U.S. Preventive Services Task Force

University of Chicago

Vapor King

Volcano Fine Electronic Cigarettes

Watson Pharmaceuticals

White Cloud Electronic Cigarettes